Myasthenia gravis

Orphanet Journal of Rare Diseases

Volumn 2, Issue 1, 2007, Pages

  Juel, Vern C ^a   Massey, Janice M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; MYASTHENIA GRAVIS; PATHOPHYSIOLOGY; REVIEW;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MYASTHENIA GRAVIS;

EID: 38349086162     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-2-44     Document Type: Article

References (95)

1. Evoli A, Tonali PA, Padua L, Lo Monaco M, Scuderi F, Batocchi AP, Marino M, Bartoccioni E: Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Not Med 2001, 7:365-368.
3. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A: Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
4. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A: Clinical aspects of MuSK antibody positive seronegative myasthenia gravis (SNMG). Neurology 2003, 60:1978-1980.
5. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C, Bartoccioni E: Anti-PI 10 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002, 82:1139-1146.
6. Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, KeeseyJC, Penn AS, Sanders DB: Myasthenia gravis: Recommendations for clinical research standards. Neurology 2000, 55:16-23.
7. Phillips LH 2nd: The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003, 998:407-412.
8. Phillips LH 2nd, Torner JC: Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996, 47:1233-1238.
9. Aragones JM, Bolibar I, Bonfill X, Mummany A, Alonso F, Illa I: Myasthenia gravis. A higher than expected incidence in the elderly. Neurology 2003, 60:1024-1026.
10. Grob D: Course and management of myasthenia gravis. JAMA 1953, 153:529-532.
11. Grob D, Brunner NG, Namba T: The natural course of myasthenia gravis and effects of therapeutic measures. Ann NY Acad Sci 1981, 377:652-669.
12. Andrews PI: Autoimmune myasthenia gravis in childhood. Semin Neurol 2004, 24:101-110.
13. Santa T, Engel AG, Lambert EH: Histomeric study of neuromuscular junction ultrastructure I. Myasthenia gravis. Neurology 1972, 22:71-82.
14. Namba T, Brunner NG, Grob D: Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine 1978, 57:411-433.
15. Phillips LH 2nd, Melnick PA: Diagnosis of myasthenia gravis in the 1990s. Semin Neurol 1990, 10:62-69.
16. Dirr LY, Donofrio PD, Patton JF, Troost BT: A false-positive edrophonium test in a patient with a brainstem glioma. Neurology 1989, 39:865-867.
17. Moorthy G, Behrens MM, Drachman DB, Kirkham TH, Knox DL, Miller NR, Slamovitz TL, Zinreich SJ: Ocular pseudomyasthenia or ocular myasthenia "plus": A warning to clinicians. Neurology 1989, 39:1150-1154.
18. Mulder DW, Lambert EH, Eaton LM: Myasthenic syndrome in patients with ALS. Neurology 1959, 9:627-631.
19. Ragge NK, Hoyt WF: Midbrain myasthenia: fatigable ptosis, lid twitch sign, and ophthalmoparesis from a dorsal midbrain glioma. Neurology 1992, 42:917-919.
20. Howard JF, Sanders DB, Massey JM: The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994, 12:305-330.
21. Stålberg EV, Trontelj JV: Single fiber electromyography: studies in healthy and diseased muscle 2nd edition. New York: Raven Press; 1994.
22. AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine: Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Summary statement. Muscle Nerve 2001, 24:1236-1238.
23. Sanders DB, Howard JF: Disorders of neuromuscular transmission. In Neurology in clinical practice I st edition. Edited by: Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Boston: Butterworth-Heinemann; 1991:1819-1842.
24. Lindstrom J: An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977, 7:36-43.
25. Vincent A, Newsom-Davis J: Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985, 48:1246-1252.
26. Andrews PI, Massey JM, Sanders DB: Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology 1993, 43:977-982.
27. Lennon VA: Serological diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In Handbook of Myasthenia Gravis and Myasthenic Syndromes Edited by: Lisak RP. New York: Marcel-Dekker; 1994:149-164.
28. Sanders DB, Andrews I, Howard JF, Massey JM: Seronegative myasthenia gravis. Neurology 1997, 48(Suppl 5):S40-S45.
29. Howard FM Jr, Lennon VA, Finley J, MatsumotoJ, Elveback LR: Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann NY Acad Sci 1987, 505:526-538.
30. Cikes N, Momoi MY, Williams CL, Howard FM Jr, Hoagland HC, Whittingham S, Lennon VA: Striational autoantibodies: Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Moyo Clin Proc 1988, 63:474-481.
31. Sanders DB, Massey JM: The diagnostic utility of anti-striational antibodies in myasthenia gravis [abstract]. Neurology 2002, 58:A229.
32. Somnier FE, Engel PJ: The occurrence of anti-titin antibodies and thymomas: A population survey of MG 1970-1999. Neurology 2002, 59:92-98.
33. Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L, Bourquin C, Bach JF, Garchon HJ: Anti-titin antibodies in myasthenia gravis. Tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001, 58:885-890.
34. Mygland A, Aarli JA, Matre R, Gilhus NE: Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994, 57:843-846.
35. Chagnac Y, Hadanin M, Goldhammer Y: Myasthenic crisis after intravenous administration of iodinated contrast agent. Neurology 1985, 35:1219-1220.
36. Canal N, Franceschi M: Myasthenic crisis precipitated by iothalamicacid. Lancet 1983, 1:1288.
37. Frank JH, Cooper GW, Black WC, Phillips LH: Iodinated contrast agents in myasthenia gravis. Neurology 1987, 37:1400-1402.
38. Juel VC, Massey JM: Autoimmune myasthenia gravis: Recommendations for treatment and immunologic modulation. Curr Treat Options Neurol 2005, 7:3-14.
39. McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, Goldfarb RH, Kitson RP, Miller AH, Spencer RL, Weiss JM: The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Rev 1997, 23:79-133.
40. Pascuzzi RM, Coslett HB, Johns TR: Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients. Ann Neurol 1984, 15:291-298.
41. Johns TR: Long-term corticosteroid treatment of myasthenia gravis. Ann NY Acad Sci 1987, 505:568-583.
42. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR: Corticosteroids for myasthenia gravis. Cochrane Database of Systematic Reviews 2005, 2:CD002828.
43. Miller RG, Milner-Brown HS, Mirka A: Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986,36:729-732.
44. Seybold ME, Drachman DB: Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment. N Engl J Med 1974, 290:81-84.
45. Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F: Myasthenia gravis: prolonged treatment with steroids. Neurology 1984, 34:170-174.
46. Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998, 50:1778-1783.
47. Herrllinger U, Weller M, Dichgans J, Melms A: Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis. Ann Neurol 2000, 47:682-683.
48. Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV: Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988, 38:258-261.
49. Kissel JT, Levy RJ, Mendell JR, Griggs RC: Azathioprine toxicity in neuromuscular disease. Neurology 1986, 36:35-39.
50. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993, 681:539-551.
51. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB: Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000, 55:448-450.
52. Sanders DB, Howard JF: Disorders of neuromuscular transmission. In Neurology in clinical practice 3rd edition. Edited by: Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Boston: Butterworth-Heinemann; 2000:2167-2185.
53. Sollinger HW, Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60:225-232.
54. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB: Mycophenolate mofetil: A safe and promising immunosup-pressant in neuromuscular diseases. Neurology 2001, 56:94-96.
55. Ciafaloni E, MasseyJM, Tucker-Lipscomb B, Sanders DB: Mycophenolate mofetil for myasthenia gravis: An open-label pilot study. Neurology 2001, 56:97-99.
56. Meriggioli MN, Rowin J, Richman JG, Leurgans S: Mycophenolate mofetil for myasthenia gravis: A double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003, 998:494-499.
57. Sanders D, McDermott M, Thornton C, Tawil A, Barohn R, the Muscle Study Group: A trial of mycophenolate mofetil (MMF) with prednisone as initial immunotherapy in myasthenia gravis (MG) [abstract]. Neurology 2007, 68:A107.
58. Vernino S, Salomao DR, Habermann TM, O'Neill BP: Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005, 65:639-641.
59. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB: Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003, 61:1438-1440.
60. NIH Consensus Conference: The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986, 256:1333-1337.
61. Pinching AF, Peters DK, Newsom-Davis J: Remission of myasthenia gravis following plasma exchange. Lancet 1976, 2:1373-1376.
62. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE: Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977, 297:1134-1140.
63. Antozzi C, Gemma M, Regi B, Berta E, Confalonieri P, Peluchetti D, Mantegazza R, Baggi F, Marconi M, Fiacchino F, et al.: A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol 1991, 238:103-107.
64. Gajdos P, Chevret S, Toyka K: Plasma exchange for myasthenia gravis. Cochrane Database of Systematic Reviews 2002, 4:CD002275.
65. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997, 41:789-796.
66. Qureshi Al, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT: Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999, 52:629-632.
67. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD: Myasthenie crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993, 50:837-840.
68. Gajdos P, Chevret S, Toyka K: Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2006, 19(2):CD002277.
69. Huang C-S, Hsu H-S, Kao K-P, Huang M-H, Huang B-S: Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand 2003, 108:136-138.
70. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S, Myasthenia Gravis Clinical Study Group: Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1g/kg versus 2g/kg: A randomized double blind clinical trial. Ann Neurol 2005, 62:1689-1693.
71. Tan E, Hajinazarian M, Bay W, Neff J, Mendel JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993, 50:137-139.
72. Caress JB, Cartwright MS, Donofrio PD, Peacock JE: The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003, 60:1822-1824.
73. Blalock A, Harvey AM, Ford FR, Lilienthal JL Jr: The treatment of myasthenia gravis by removal of the thymus gland. J American Medical Association 1941, 117:1529-1533.
74. Blalock A: Thymectomy in the treatment of myasthenia gravis. Report of twenty cases. J Thorac Surg 1944, 13:316-339.
75. Wolfe GI, Kaminski HJ, Jaretzki A III, Swan A, Newsom-Davis J: Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann NY Acad Sci 2003, 998:473-480.
76. A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone (MGTX) [http://www.soph.uab.edu/mgtx/]. Accessed 15 March 2007
77. Gronseth GS, Barohn RJ: Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:7-15.
78. Perlo VP, Arnason B, Poskanzer D, Castleman B, Schwab RS, Osserman KE, Papatestis A, Alpert L, Kark A: The role of thymectomy in the treatment of myasthenia gravis. Ann NY Acad Sci 1971, 183:308-315.
79. Rodriguez M, Gomez MR, Howard FM, Taylor WF: Myasthenia gravis in children: Long-term follow-up. Ann Neurol 1983, 13:504-510.
80. Mulder DG, Graves M, Hermann C: Thymectomy for myasthenia gravis: Recent observation and comparisons with past experience. Ann Thorac Surg 1989, 48:551-555.
81. Monden Y, Nakahara K, Kagotani K, Fujii Y, Nanjo S, Masaoka A, Kawashima Y: Effects of preoperative duration of symptoms on patients with myasthenia gravis. Ann Thorac Surg 1984, 38:287-291.
82. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, Lombardi M, Mantegazza R, Monticelli ML, Piccolo G, et al.: Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients. J Neurol Sci 1991, 106:213-220.
83. Lanska DJ: Indications for thymectomy in myasthenia gravis. Neurology 1990, 40:1828-1829.
84. Schumm F, Wietholter H, Fateh-Moghadam A, Dichgans J: Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 1985, 48:332-337.
85. Jaretzki A III: Thymectomy for myasthenia gravis: Analysis of the controversies regarding technique and results. Neurology 1997, 48(Suppl 5):S52-S63.
86. Jaretzki A III, Steinglass KM, Sonett JR: Thymectomy in the management of myasthenia gravis. Semin Neurol 2004, 24:49-62.
87. Jaretzki A III, Aarli JA, Kaminski HJ, Phillips LH, Sanders DB: Preoperative preparation of patients with myasthenia gravis forestalls postoperative respiratory complications after thymectomy. Ann Thorac Surg 2003, 75:1068.
88. Bulkley GB, Bass KN, Stephenson GR, Diener-West M, George S, Reilly PA, Baker RR, Drachman DB: Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg 1997, 226:324-334.
89. Oosterhuis HJ: The natural course of myasthenia gravis: A long-term followup study. J Neurol Neurosurg Psychiatry 1989, 52:1121-1127.
90. Sellman MS, Mayer RF: Treatment of myasthenic crisis in late life. South Med J 1985, 78:1208-1210.
91. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, Brannagan TH, Fink ME, Rowland LP: Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997, 48:1253-1260.
92. Pascuzzzi RM: Medications and myasthenia gravis: A reference for health care professionals. [http://myasthenia.org/docs/MGFAMedicationsandMG.pdf]. Accessed 15 March 2007
93. Osserman KE: Myasthenia gravis New York: Grune & Stratton; 1958:78-80.
94. Simpson JA, Thomaides T: Treatment of myasthenia gravis: An audit. Q J Med 1987, 64:693-704.
95. Grob D: Natural history of myasthenia gravis. In Myasthenia gravis and myasthenic disorders Edited by: Engel AG. New York: Oxford University Press; 1999:131-154.